We are live on ! Find out more
DMAC icon

DiaMedica Therapeutics
DMAC

39 hedge funds and large institutions have $14.9M invested in DiaMedica Therapeutics in 2021 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

86% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 7

32% more capital invested

Capital invested by funds: $11.2M → $14.9M (+$3.65M)

15% more funds holding

Funds holding: 34 → 39 (+5)

0.18% more ownership

Funds ownership: 14.93% → 15.11% (+0.18%)

54% less call options, than puts

Call options by funds: $138K | Put options by funds: $302K

Holders
39
Holders Change
+5
Holders Change %
+14.71%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
13
Reduced
7
Closed
3
Calls
$138K
Puts
$302K
Net Calls
-$164K
Net Calls Change
+$129K

Top Buyers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
+$4.04M
2
AFM
Anson Funds Management
Texas
+$511K
3
CLG
Cooperman Leon G
+$393K
4
Two Sigma Investments
Two Sigma Investments
New York
+$261K
5
Citadel Advisors
Citadel Advisors
Florida
+$117K

Top Sellers

Rank Fund Capital Flow
1
MHP
Manatuck Hill Partners
Connecticut
-$504K
2
IC
Ikarian Capital
Texas
-$400K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$182K
4
BFM
Boothbay Fund Management
New York
-$40.4K
5
Simplex Trading
Simplex Trading
Illinois
-$39.2K
Name Holding Trade Value Shares
Change 		Change in
Stake
Simplex Trading
26
Simplex Trading
Illinois
$23K -$39.2K -9,991 -61%
MPWT
27
MassMutual Private Wealth & Trust
Connecticut
$18K – – –
UBS Group
28
UBS Group
Switzerland
$17K +$18.1K +4,618 New
US Bancorp
29
US Bancorp
Minnesota
$16K – – –
TWC
30
TD Waterhouse Canada
Ontario, Canada
$8.33K +$7.22K +1,840 New
NFSG
31
Newbridge Financial Services Group
Florida
$6K – – –
PFGIA
32
Patriot Financial Group Insurance Agency
Massachusetts
$4K – – –
SCA
33
Sandy Cove Advisors
Massachusetts
$4K +$4.71K +1,200 New
Royal Bank of Canada
34
Royal Bank of Canada
Ontario, Canada
$3K -$5.89K -1,500 -65%
Wells Fargo
35
Wells Fargo
California
$1K +$185 +47 +41%
FDCDDQ
36
Federation des caisses Desjardins du Quebec
Quebec, Canada
$858 – – –
Barclays
37
Barclays
United Kingdom
– -$19K -4,616 Closed
GCM
38
Gables Capital Management
Florida
– -$2K -542 Closed
Bank of America
39
Bank of America
North Carolina
– +$12 +3 New
FCA
40
FinTrust Capital Advisors
South Carolina
– +$294 +75 New
1
2

DMAC Hedge Fund Activity: Q4 2021 in Review

39 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q4 2021, worth a combined $14.9M — up 32% from $11.2M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new DMAC positions and 3 closed out — a net gain of 5 holders — while 13 added to existing stakes and 7 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $4.04M. The largest seller was Manatuck Hill Partners, cutting an estimated $504K.

  • 39 institutional investors held DiaMedica Therapeutics (DMAC) as of Q4 2021, up from 34 in Q3 2021.
  • Funds reported $14.9M of DiaMedica Therapeutics stock for Q4 2021, up 32% quarter-over-quarter.
  • 8 funds opened new DiaMedica Therapeutics positions in Q4 2021 and 3 closed out, a net change of +5 holders.
  • The largest DiaMedica Therapeutics buyer in Q4 2021 was Stonepine Capital Management, an estimated $4.04M added.
  • The largest DiaMedica Therapeutics seller in Q4 2021 was Manatuck Hill Partners, an estimated $504K sold.

Based on aggregated 13F filings for Q4 2021.